SENATE-BILL 2292: S.2292 - Over-the-Counter Monograph Drug User Fee Amendments
AI-Powered Summary
SENATE-BILL 2292 aims to amend the Federal Food, Drug, and Cosmetic Act to enhance the regulation and availability of over-the-counter (OTC) monograph drugs by streamlining the user fee program. The legislation addresses major themes of public health, consumer access to safe medications, and regulatory transparency. Key provisions include the establishment of user fees for OTC drugs, which may influence their cost and availability, and a requirement for the FDA to report on regulatory progress, thereby promoting accountability. The bill emphasizes the use of voluntary consensus standards for testing procedures, potentially improving drug quality. Implementation will involve the FDA adapting its regulatory processes to incorporate these fees and reporting requirements, although specific timelines are not detailed. Potential impacts include improved access to safe medications for consumers, though concerns about transparency and public participation in the regulatory process may arise, highlighting the balance between revenue generation and public health priorities.
Demographic Impact Analysis
Summary
Overall Constitutional Implications
The bill's provisions regarding user fees for OTC drugs could create barriers to access for various demographic groups, particularly those with lower incomes or specific health needs. This raises constitutional concerns about equal protection and the right to health.
Key Individual Rights Affected
- Right to Health and Safety
- Equal Protection under the Law
- Due Process in Regulatory Processes
Constitutional Provisions
- Fourteenth Amendment - Equal Protection Clause
- Fifth Amendment - Due Process Clause
Potential Constitutional Challenges
The bill may face challenges based on its disproportionate impact on low-income individuals and marginalized groups, arguing that it violates equal protection principles. Additionally, the lack of transparency in the regulatory process could lead to due process concerns.
Summary
SENATE-BILL 2292 aims to streamline the regulatory framework for OTC drugs but raises significant constitutional implications regarding individual rights. The potential for increased costs and reduced access to essential medications could disproportionately affect vulnerable populations, leading to violations of equal protection and due process rights. The bill's impact on public health must be balanced against these constitutional concerns to ensure equitable treatment for all individuals.
Constitutional Analysis
This bill has been analyzed for constitutional compliance using AI-powered analysis of constitutional principles and precedents.
Analysis generated using AI-powered review of constitutional principles and legal precedents.
Take Action
Text 50409
💡 How to use:
These links will start a conversation with ResistBot. When prompted, mention S. 2292 to reference this bill.
Contact Your Representatives
Write to YOUR elected officials about this bill
Rate This Bill
Sign in to save a private rating for this bill and track your civic engagement over time.
Sign In FreePolicy Topics
Timeline
July 15, 2025
Bill Introduced
Current
Reported by Committee
June 12, 2026
Last Updated
Ask the Constitutional AI About This Bill
Sign in free to chat with our constitutional analysis AI about this bill — get plain-English explanations, constitutional concerns, and demographic impact estimates personalized to you.
Sign In Free to Chat